Equities research analysts expect GW Pharmaceuticals PLC- (NASDAQ:GWPH) to report $63.37 million in sales for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for GW Pharmaceuticals PLC-‘s earnings. The lowest sales estimate is $40.62 million and the highest is $149.90 million. GW Pharmaceuticals PLC- reported sales of $3.46 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 1,731.5%. The firm is expected to issue its next earnings results on Tuesday, August 6th.
According to Zacks, analysts expect that GW Pharmaceuticals PLC- will report full-year sales of $218.50 million for the current fiscal year, with estimates ranging from $169.27 million to $303.80 million. For the next fiscal year, analysts anticipate that the company will post sales of $542.45 million, with estimates ranging from $360.07 million to $879.00 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover GW Pharmaceuticals PLC-.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($1.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.48) by $0.80. GW Pharmaceuticals PLC- had a negative net margin of 458.79% and a negative return on equity of 45.75%. The firm had revenue of $39.20 million during the quarter, compared to the consensus estimate of $12.32 million. During the same period last year, the firm posted ($3.12) EPS. The firm’s quarterly revenue was up 1189.5% on a year-over-year basis.
Shares of GWPH stock opened at $178.98 on Thursday. GW Pharmaceuticals PLC- has a 12-month low of $90.14 and a 12-month high of $196.00. The stock has a market cap of $5.22 billion, a P/E ratio of -16.95 and a beta of 2.75. The company has a quick ratio of 7.19, a current ratio of 7.81 and a debt-to-equity ratio of 0.03.
In other GW Pharmaceuticals PLC- news, insider Geoffrey W. Dr Guy sold 1,200,000 shares of the firm’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $14.69, for a total value of $17,628,000.00. Following the completion of the sale, the insider now owns 8,465,528 shares in the company, valued at approximately $124,358,606.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Justin D. Gover sold 11,112 shares of the firm’s stock in a transaction dated Tuesday, February 26th. The shares were sold at an average price of $12.45, for a total transaction of $138,344.40. Following the completion of the sale, the chief executive officer now owns 392,885 shares of the company’s stock, valued at approximately $4,891,418.25. The disclosure for this sale can be found here. Insiders sold a total of 3,003,864 shares of company stock valued at $44,626,122 in the last 90 days. Corporate insiders own 5.50% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of GWPH. Canada Pension Plan Investment Board increased its position in GW Pharmaceuticals PLC- by 327.3% in the 4th quarter. Canada Pension Plan Investment Board now owns 1,175,000 shares of the biopharmaceutical company’s stock valued at $114,424,000 after acquiring an additional 900,000 shares in the last quarter. Marshall Wace North America L.P. increased its position in GW Pharmaceuticals PLC- by 1,564.3% in the 1st quarter. Marshall Wace North America L.P. now owns 316,899 shares of the biopharmaceutical company’s stock valued at $53,419,000 after acquiring an additional 297,858 shares in the last quarter. ETF Managers Group LLC acquired a new stake in GW Pharmaceuticals PLC- in the 4th quarter valued at about $18,150,000. Victory Capital Management Inc. increased its position in GW Pharmaceuticals PLC- by 80.4% in the 1st quarter. Victory Capital Management Inc. now owns 408,940 shares of the biopharmaceutical company’s stock valued at $68,935,000 after acquiring an additional 182,210 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in GW Pharmaceuticals PLC- in the 4th quarter valued at about $15,685,000. Hedge funds and other institutional investors own 79.60% of the company’s stock.
About GW Pharmaceuticals PLC-
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
Recommended Story: Balanced Fund
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.